Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: DrJerry who wrote (13440)	1/17/1998 10:34:00 PM
From: Proton	Read Replies (1) \| Respond to of 32384

Re: Reminder of a Nice Technical Call Welcome back, Dr. J.! I wanted to compliment you on a call you made on December 27: Dr. J's failsafe chart says that when LGND charts are at bottom (Dec. 24) and the stock declines on that day but the warrants have an up-day (resulting in significant increase in time premium) that it is time to jump back in. I may be daffy but I don't see lgnd prices under 11 and I don't see warrant prices under 6... LGND has been a jumpy little beast since then, but your levels haven't been hit, and the stock is up nicely since then (even with the retracement). So, does the same pattern hold at intermediate tops? That is, when LGND goes up into a peak and LGNDW goes down, can we infer that to be a good signal to sell? Pý

To: DrJerry who wrote (13440)	1/17/1998 10:42:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

DrJerry, I agree that the word is not getting out as quickly as I would like. Having LLY as a partner might help because I do think that they will be jumping on board with both feet because the market is huge and they really need to fill the hole that will be left when blockbusters like Prozac go off patent in 2002. So far, Targretin Type II diabetes trials have only been done in Europe and when the US trials start, more research centers should be aware of Targretin and 2nd generation Rexinoids. It is pretty sad to see that an internet search of "Rexinoid" brings up only my posts and pages.

To: DrJerry who wrote (13440)	1/18/1998 5:09:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

DrJerry, Actually, I think that IR got the word out on this one a couple of months ago. It is one of the three articles that I expected quite some time ago. All took longer than I expected, but this is the one that I thought would reach the widest audience and it definitely is more positive and detailed than the Financial Time's article. The Business Week article was the strongest, but it would be unusual to get such as strong article into the printed version. I think that the NY Times makes it clear to investors where the best play would be. I expect LGND and LLY PR to get things rolling. As LLY sets the stage for the US trials (and I expect several including Targretin as monotherapy for early cases and combination therapy with insulin, Rezulin, Metformin, and sulfanylureas, as well as IND filings for one of teh second generation rexinoids, LGD1268 or LGD1324), more physicians at research centers will learn about Targretin's diabetes applications (I think that they already know about cancer treatment). FDA reform should go into effect this year, allowing off label promotion. I would think that the European data would be very useful for getting the word out to practicing physicians in the US who could begin prescribing it off label next year. Of course, getting the word out to physicians who have money to invest is something that should be done now. LGND's price is very attractive and physicians looking to invest in biotechs probably could use a little education on Ligand.